Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations facility located in Sanand, Ahmedabad, Gujarat. The USFDA has classified the inspection status of this facility as Voluntary Action Indicated (VAI), signifying that the inspection is now closed. This update follows a previous intimation regarding the inspection conducted between May 06, 2026, and May 15, 2026. The VAI classification is generally viewed positively by the market as it indicates no major compliance issues requiring significant corrective actions.

Emcure Pharmaceuticals Ltd has announced that its 45th Annual General Meeting (AGM) will be held on Monday, September 21, 2026, at 11:00 a.m. IST via Video Conferencing. The company's Board of Directors had previously recommended a final dividend of ₹3.60 per equity share (36%) for the financial year ended March 31, 2026. The record date for determining the entitlement of members to this final dividend has been fixed as Friday, September 04, 2026. If approved at the AGM, the dividend payment will be made within 30 days of the approval, subject to applicable taxes.

Emcure Pharmaceuticals Ltd announced significant changes in its Board composition. Mr. Berjis Desai, Chairman and Non-executive, Non-Independent Director, will cease to hold office upon the conclusion of the upcoming Annual General Meeting (AGM) due to his appointment to the National Commission for Minorities. The company also appointed Mr. Raghu Kumar as an Additional Director (Non-Executive and Independent) effective August 6, 2026, for a three-year term, subject to member approval. Furthermore, Mr. Satish Mehta, currently Managing Director & CEO, will assume the role of Chairman from the conclusion of the ensuing AGM, succeeding Mr. Desai.

Emcure Pharmaceuticals Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results, which were reviewed and recommended by the Audit Committee. The company submitted the results along with Limited Review Reports from statutory auditors B S R & Co. LLP, as per SEBI Listing Regulations. A press release detailing key updates on these results was also enclosed.

Emcure's consolidated revenue rose 22.8% YoY to ₹2,580.4 Cr in Q1 FY27 (+4.5% QoQ from ₹2,469.7 Cr), while PAT grew faster, up 36.2% YoY to ₹292.5 Cr — the company's own adjusted-PAT measure, which strips out forex and one-offs, grew a still-strong 33.8% YoY to ₹290.9 Cr, confirming the growth isn't primarily one-off driven. QoQ, PAT rose 20.0% off a ₹243.7 Cr base. PAT margin expanded to 11.3%, up 110 bps YoY and 140 bps QoQ. No exceptional items hit the P&L this quarter, unlike Q1 FY26 which absorbed a ₹3.5 Cr one-time legal-settlement cost, so the YoY comparison is close to clean. International revenue did the heavy lifting, up 34.2% YoY to ₹1,485.1 Cr (57.6% of the mix): Europe grew 32.8% to ₹536.7 Cr on a stronger Liposomal Amphotericin B contribution, Canada grew 24.6% to ₹426.6 Cr, and Rest of World grew 44.8% to ₹521.8 Cr on ARV strength. Domestic grew a slower 10.2% to ₹1,095.3 Cr, helped by CNS, cardiology and women's-health brands plus an execution turnaround at Zuventus. Gross margin compressed 340 bps YoY to 58.4% as the lower-margin international mix grew, but EBITDA margin still expanded 50 bps YoY to 19.7% (EBITDA ₹508.0 Cr, +25.8% YoY) on employee-cost leverage (+4.1% YoY, well below revenue growth), even as freight-cost volatility pushed other expenses up 17.7% YoY. Management's FY27 guidance (from the Q4 FY26 call) called for low-to-mid-teen revenue growth and 75-100 bps of full-year EBITDA margin expansion; Q1's 22.8% revenue growth runs well ahead of that band, a beat, while the 50 bps of margin gain trails the low end of the guided full-year pace — a gap pre-result commentary (CompoundingAI's Q1 FY27 preview, no numeric consensus available) had flagged as a freight/solvent-cost risk, and it partly materialized, though margin still expanded rather than compressed. On the standalone entity, PAT was ₹200.1 Cr against the group's ₹292.5 Cr, meaning subsidiaries (Zuventus, Tillomed, Gennova and the LatAm/Africa units) contributed roughly ₹92 Cr of the quarter's profit. The quarter also carried three corporate actions outside the P&L: Emcure completed the buyout of the 12.05% minority stake in Gennova Biopharmaceuticals, making it a wholly owned subsidiary effective July 21; Gennova concurrently divested its mRNA business for ₹139.5 Cr; and the Sanand manufacturing facility was placed under US FDA Import Alert 66-40 on July 21 — a risk not addressed in management's press release, though external preview commentary pegs direct US exposure at under 3% of revenue. Management's press release framed Q1 as "an encouraging early signal" for FY27, the second year of its five-year plan, crediting productivity gains and operating leverage for the margin print — a claim the numbers broadly support, since PAT growth (36.2%) outran revenue growth (22.8%) even with gross-margin compression. The open questions into Q2: whether EBITDA margin expansion accelerates toward the guided 75-100 bps annual pace as freight costs normalize, and how quickly the Sanand import alert and the newly wholly-owned, now mRNA-divested Gennova show up in the group's numbers.

Emcure Pharmaceuticals Ltd has announced the completion of its acquisition of 663,865 equity shares, representing 12.05% of Gennova Biopharmaceuticals Limited (Gennova), for an aggregate consideration of ₹2,318.7 Million. This acquisition, finalized on July 21, 2026, makes Gennova a wholly-owned subsidiary of Emcure. Gennova, involved in biotechnology R&D, manufacturing, and marketing, had a turnover of ₹4,917.42 Million and PAT of ₹54.25 Million for the financial year ended March 31, 2026. The transaction was conducted at arm's length, despite Gennova being a related party due to Emcure's existing 87.95% shareholding.

Emcure Pharmaceuticals Ltd has announced that Mr. P.S. Jayakumar will complete his second consecutive term as an Independent Director on July 21, 2026. Consequently, he will cease to be a Director of the company and will also step down as Chairman of the Audit Committee and Member of the Nomination and Remuneration Committee and Risk Management Committee. The Board expressed its appreciation for his contributions during his tenure.

Emcure Pharmaceuticals Ltd announced that its co-marketed brand Poviztra®, containing innovator semaglutide, has received CDSCO approval for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3). This approval makes semaglutide the first GLP-1 receptor agonist approved in India for MASH, addressing a significant unmet medical need. Poviztra® is manufactured and imported from Novo Nordisk's European facility. The expansion leverages Emcure's subsidiary Zuventus Healthcare's portfolio to increase MASH awareness, diagnosis, and treatment. The approval is supported by Phase III ESSENCE trial data showing semaglutide's efficacy in resolving steatohepatitis and improving liver fibrosis. This marks an important milestone for patients with this serious liver disease.

Emcure Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for the first quarter of the fiscal year 2027, both on a standalone and consolidated basis. The company has also confirmed that the trading window for designated persons and their relatives, which closed on July 1, 2026, will remain shut until 48 hours after the declaration of these financial results, specifically until August 8, 2026, in compliance with insider trading regulations.

Emcure Pharmaceuticals Limited has consolidated its ownership in its biopharma subsidiary, Gennova Biopharmaceuticals Limited, by acquiring the entire 12.05% minority stake held by Dr. Sanjay Singh and others. This move makes Gennova a wholly owned subsidiary of Emcure. The company is sharpening its focus on biologics and biosimilars, with Gennova now under the leadership of Mr. Samit Mehta. Gennova will concentrate on its biologics franchise, biosimilars development, and adjacent therapeutic platforms. Emcure stated that this transaction is not expected to materially impact its consolidated financials or capital allocation framework, with deleveraging, capex, and R&D plans remaining unchanged.